Impact of pulmonary exposure to gold core silver nanoparticles of different size and capping agents on cardiovascular injury

Table 2 Lung BAL cell differentials and protein

	% Macrophages	% Neutrophils	% Eosinophils	% Lymphocytes	% Epithelial Cells	Protein (mg/mL)
1 Day
Citrate	96.0 ± 0.7	0.1 ± 0.1	0.1 ± 0.1	0.1 ± 0.1	3.8 ± 0.7	0.2 ± 0.1
20 nm AgNP	91.8 ± 1.2^b	1.4 ± 1.3	0.4 ± 0.3	1.1 ± 0.3	5.3 ± 0.5	0.4 ± 0.1
110 nm AgNP	91.1 ± 0.5^b	0.6 ± 0.6	0.8 ± 0.4	0.3 ± 0.1	7.0 ± 0.3^b	0.4 ± 0.0
PVP	95.2 ± 0.9	0.1 ± 0.1	0.4 ± 0.3	0.8 ± 0.6	3.5 ± 0.5	0.6 ± 0.1
20 nm AgNP	92.3 ± 0.9^b	0.6 ± 0.1	0.3 ± 0.2	0.3 ± 0.2	6.4 ± 1.0	0.8 ± 0.1^b
110 nm AgNP	91.9 ± 0.8^b	0.0 ± 0.0	0.4 ± 0.4	0.7 ± 0.2	7.0 ± 0.9	0.8 ± 0.1^b
7 Day
Citrate	88.8 ± 4.7	0.4 ± 0.2	0.1 ± 0.1	1.1 ± 0.6	9.6 ± 4.3	0.2 ± 0.0
20 nm AgNP	96.9 ± 0.9^b	1.3 ± 1.0	0.2 ± 0.2	0.9 ± 0.4	0.7 ± 0.1^b	0.3 ± 0.2
110 nm AgNP	96.8 ± 1.4^b	0.6 ± 0.3	0.1 ± 0.1	2.0 ± 0.9	0.5 ± 0.3^b	0.2 ± 0.1
PVP	95.3 ± 1.0	0.6 ± 0.3	0.1 ± 0.1	1.5 ± 0.6	2.5 ± 1.1	0.2 ± 0.0
20 nm AgNP	90.7 ± 3.9	3.6 ± 2.7	0.2 ± 0.2	3.1 ± 2.3	2.5 ± 0.9	0.2 ± 0.0
110 nm AgNP	94.2 ± 1.5	1.0 ± 0.5	0.3 ± 0.2	1.2 ± 0.6	3.3 ± 2.0	0.1 ± 0.0^b,c

Calculated percentage of total cell BALF pellet and protein quantification. ^bdenotes significant (p < 0.05) versus vehicle, ^cdenotes significance from other AgNP particle size within a capping agent, calculated by one-way ANOVA with Tukey Post Hoc test Values expressed mean ± SEM, n = 4–8

ISSN: 1743-8977